Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Endocr Pract ; 2024 Jun 14.
Article in English | MEDLINE | ID: mdl-38880348

ABSTRACT

BACKGROUND: Over the past millennia, the evaluation and management of thyroid nodules has essentially remained the same with thyroidectomy as the only reliable method to identify malignancy. However, in the last 30 years, technological advances have significantly improved diagnostic management of thyroid nodules. Advances in imaging have allowed development of a reliable risk- based stratification system to identify nodules at increased risk of malignancy. At the same time, sensitive imaging has caused collateral damage to the degree that we are now identifying and treating many small, low risk nodules with little to no clinical relevance. OBJECTIVE: To review the history of thyroid nodule evaluation with emphasis on recent changes and future pathways. METHODS: Literature review and discussion. RESULTS: Thyroid ultrasound remains the best initial method to evaluate the thyroid gland for nodules. Different risk-of-malignancy protocols have been developed and introduced by different societies, reporting methods have been developed and improved each, with goals of improving the ability to recognize nodules requiring further intervention and minimizing excessive monitoring of those who do not. Once identified, cytological evaluation of nodules further enhances malignancy identification with molecular markers assisting in ruling out malignancies in indeterminate nodules preventing unneeded intervention. And all societies have urged avoidance of overdiagnosis and overtreatment of low-risk cancers of little to no clinical relevance. CONCLUSION: In this review, we describe advancements in nodule evaluation and management, while emphasizing caution in overdiagnosing and overtreating low-risk lesions without clinical importance.

2.
J Endocr Soc ; 8(3): bvad165, 2024 Jan 16.
Article in English | MEDLINE | ID: mdl-38249431

ABSTRACT

Context: Nonalcoholic fatty liver disease, renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common cause of chronic liver disease with an estimated worldwide prevalence of 30.1% while clinical practice observations reflect a disproportionately lower prevalence of 1.9%, indicating a condition that is underrecognized in clinical care settings. Screening for MASLD is rarely performed, and little is known about the prevalence in Hawai'i. Objective: This pilot aims to develop an understanding of the prevalence and factors associated with MASLD in Hawai'i's adolescent and young adult (AYA) population. Design/Methods: Cross-sectional observational pilot study: We used Fibroscan®-liver ultrasonographic vibration-controlled transient elastography (VCTE) to identify MASLD based on controlled attenuation parameter (CAP) scores ≥238 (dB/m) and collected biometric, anthropometric, and Beverage Intake Questionnaire (sugar-sweetened beverage) survey data. Setting: The study took place at community clinics in Hawai'i on the island of O'ahu. Participants: One hundred individuals were evaluated, age 14 to 34 years. Main Outcome Measures: We used VCTE Fibroscan® with CAP scoring to identify the presence of hepatocyte steatosis (fatty liver). Results: Overall MASLD prevalence in the sample was 44% (95% confidence interval: 34.1%-54.3%). In participants with MASLD, obese Native Hawaiian and other Pacific Islanders (62%) and nonobese Asians (43%) had the highest rates of MASLD. Conclusion: This pilot evaluation of the AYA NHOPI and Asian MASLD population in Hawai'i shows a higher rate of MASLD than those reported in other parts of the United States. Larger population health studies are indicated to expand our knowledge of MASLD in the Hawaiian Islands.

3.
Plast Reconstr Surg ; 145(2): 316e-323e, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31985627

ABSTRACT

BACKGROUND: Perioperative use of opioids is common in surgical practice and frequently results in troublesome opioid-related side effects that often lead to suboptimal postsurgical outcomes. As such, multiple studies have sought to identify alternatives that may reduce reliance on opioid-based perioperative pain management. Recently, it has been shown that patient education and patient involvement in care positively impact surgical outcomes. This study evaluates how patient education regarding the role of endogenous beta-endorphins in reducing pain and the opposing effect of opioid analgesics impacts opioid consumption and mood after surgery. METHODS: Patients scheduled for breast augmentation were divided into two groups, A and B. Both groups received identical multimodal anesthesia regimens; however, only patients in group B were educated on the role of endogenous beta-endorphins in pain control and mood enhancement, and how opioids block their action. RESULTS: Patients in the group receiving preoperative education on the analgesic and mood-enhancing role of endogenous beta-endorphins and how opioids block their action consumed significantly less opioids and had better postsurgical outcomes as determined by self-reported measures of pain level and mood/sense of well-being. CONCLUSIONS: The findings of this study suggest that opioid use was significantly reduced and patients' mood/sense of well-being was significantly enhanced when patients received preoperative education on the oppositional relationship between beta-endorphins and opioids. Such patient education may be linked to a significant reduction in opioid use and improved patient mood/sense of well-being, especially when combined with opioid-free multimodal anesthesia. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.


Subject(s)
Affect/drug effects , Analgesics, Opioid/adverse effects , Mammaplasty , Pain Management/methods , Patient Education as Topic/methods , Adult , Female , Humans , Prospective Studies , Young Adult
4.
J Plast Reconstr Aesthet Surg ; 73(2): 391-407, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31582320

ABSTRACT

The use of povidone-iodine alone has been advocated by several authors who continued to utilize it for pocket irrigation despite the US Food and Drug Administration (FDA)'s prohibition of 2000. However, in 2017, the FDA removed the ban against povidone-iodine use in breast augmentation. In the practice of breast augmentation, pocket irrigation with various solutions has been advocated in preventing infection and capsular contraction. However, debate continues regarding an ideal solution that is most efficacious and carries least side effects. Many studies have shown the superiority of povidone-iodine due to its broad antimicrobial spectrum, efficacy against biofilms, lack of resistance, and safe allergenic profile. Povidone-iodine is bactericidal against many multi-drug resistant organisms such as Staphylococcus aureus, Pseudomonas, Enterococcus, and Mycobacterium. In addition, povidone-iodine also has microbicidal activity against fungi, protozoa, spores, and viruses. Despite widespread clinical use and extensive testing, there have been no reports of increased tolerance or resistance to povidone-iodine in any laboratory-derived or clinical isolates to date. Meanwhile, antibiotic resistance is a growing obstacle, and virtually all Gram-negative bacteria are now resistant to bacitracin. We are pleased with the recent change in the FDA's standing on povidone-iodine use in breast implant procedures given its superior antiseptic property, excellent safety profile, lack of resistance, accessibility, and low cost.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Infective Agents, Local/administration & dosage , Breast Implantation/methods , Mammaplasty/methods , Povidone-Iodine/administration & dosage , Breast Implants/adverse effects , Drug Approval , Female , Humans , Prosthesis-Related Infections/prevention & control , Therapeutic Irrigation , United States
6.
Aesthet Surg J ; 37(8): 892-899, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28333299

ABSTRACT

BACKGROUND: Breast reduction has traditionally been performed under general anesthesia with adjunct opioid use. However, opioids are associated with a wide variety of adverse effects, including nausea, vomiting, constipation, postoperative sedation, dizziness, and addiction. OBJECTIVES: This study compares bilateral breast reduction using a multimodal opioid-free pain management regimen vs traditional general anesthesia with adjunct opioids. METHODS: A total of 83 female patients were enrolled in this study. Group 1 includes a retrospective series of 39 patients that underwent breast reduction via general anesthesia with adjunct opioid use. This series was compared to 2 prospective groups of patients who did not receive opioids either preoperatively or intraoperatively. In group 2, twenty-six patients underwent surgery under intravenous sedation and local anesthesia. In group 3, eighteen patients underwent surgery with general anesthesia. All patients in groups 2 and 3 received preoperative gabapentin and celecoxib along with infiltration of local anesthetics during the operation and prior to discharge to the Post-Anesthesia Care Unit (PACU). Primary outcome measures included the duration of surgery, time from end of operation to discharge home, postoperative opioid and antiemetic use, and unplanned postoperative hospitalizations. RESULTS: When compared to group 1, groups 2 and 3 experienced a shorter time from end of operation to discharge home (P < 0.05), fewer unplanned hospital admissions (P < 0.05), and highly significant decrease in postoperative opioid use (P < 0.001). CONCLUSIONS: This multimodal approach allows patients to safely undergo opioid-free bilateral breast reduction either under local or general anesthesia as an outpatient. This method resulted in significantly less morbidity, use of opioids postoperatively, as well as unplanned hospital admissions compared to "traditional" breast reduction under general anesthesia with the use of opioids. LEVEL OF EVIDENCE: 3.


Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Analgesics, Opioid/adverse effects , Mammaplasty/adverse effects , Pain Management/methods , Pain, Postoperative/therapy , Adult , Amines/therapeutic use , Anesthesia, General/methods , Anesthesia, Local/methods , Anesthetics, Local/administration & dosage , Celecoxib/therapeutic use , Cyclohexanecarboxylic Acids/therapeutic use , Cyclooxygenase 2 Inhibitors , Female , Gabapentin , Humans , Mammaplasty/methods , Middle Aged , Nerve Block/methods , Pain Measurement , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Preoperative Care/methods , Prospective Studies , Retrospective Studies , Time Factors , Treatment Outcome , Young Adult , gamma-Aminobutyric Acid/therapeutic use
7.
J Steroid Biochem Mol Biol ; 165(Pt A): 2-11, 2017 01.
Article in English | MEDLINE | ID: mdl-27380651

ABSTRACT

Congenital adrenal hyperplasia (CAH) refers to a group of inherited genetic disorders involving deficiencies in enzymes that convert cholesterol to cortisol within the adrenal cortex. There are five key enzymes involved in the production of cortisol. Of these key enzymes, deficiency of 21-hydroxylase is the most commonly defective enzyme leading to CAH representing more than 90% of cases. The low adrenal cortisol levels associated with CAH affects the hypothalamic-pituitary-adrenal negative feedback system leading to increased pituitary adrenocorticotropic hormone (ACTH) production, which overstimulates the adrenal cortex in an attempt to increase cortisol production resulting in a hyperplastic adrenal cortex. The deficiency of enzyme 21-hydroxylase results from mutations or deletions in the CYP21A2 gene found on chromosome 6p. The disorder is transmitted as an autosomal recessive pattern and specific mutations may be correlated to enzymatic compromise of varying degrees, leading to the clinical manifestation of 21-hydroxylase deficiency (21-OHD) CAH.


Subject(s)
Adrenal Hyperplasia, Congenital/enzymology , Adrenal Hyperplasia, Congenital/genetics , Steroid 21-Hydroxylase/metabolism , Adrenal Cortex/metabolism , Adrenocorticotropic Hormone/metabolism , Anti-Mullerian Hormone/metabolism , Cerebral Cortex/metabolism , Cholesterol/metabolism , Female , Genetic Association Studies , Genetic Testing , Genotype , Humans , Hydrocortisone/metabolism , Male , Mutation , Phenotype , Pregnancy , Prenatal Diagnosis , Steroid 21-Hydroxylase/genetics
8.
Rev Endocr Metab Disord ; 14(2): 127-31, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23743889

ABSTRACT

Human Immunodeficiency virus (HIV) infection and Acquired Immunodeficiency Syndrome (AIDS) are associated with dysfunction of many endocrine organs and their axis. HIV infectivity leads to altered metabolism, poor oral intake and increased prevalence of weight loss and wasting which may have a role in thyroid dysfunction. Overt thyroid dysfunction occurs at similar rates as the general population while subclinical disease such as nonthyroidal illness (sick euthyroid syndrome), subclinical hypothyroidism and isolated low T4 levels are more frequent. Moreover, HAART therapy can complicate thyroid function further through drug interactions and the immune reconstitution inflammatory syndrome (IRIS). In this review we report the common thyroid dysfunctions associated with HIV before and after HAART therapy. We discuss presentation, diagnostic work up, treatment and follow up in each condition.


Subject(s)
HIV Infections/drug therapy , HIV Infections/physiopathology , Thyroid Diseases/physiopathology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/metabolism , Acquired Immunodeficiency Syndrome/physiopathology , Antiretroviral Therapy, Highly Active , Graves Disease/drug therapy , Graves Disease/metabolism , Graves Disease/physiopathology , HIV Infections/metabolism , Humans , Hypothyroidism/metabolism , Hypothyroidism/physiopathology , Models, Biological , Thyroid Diseases/metabolism , Thyroid Gland/metabolism , Thyroid Gland/pathology
9.
Hawaii J Med Public Health ; 72(6): 180-4, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23795326

ABSTRACT

This study investigates the importance of communication in surgery and how delivering preoperative patient education can lead to better health outcomes postoperatively, via promoting tolerable pain scores and minimizing the use of narcotics after surgery. Patients who underwent outpatient surgery were randomly divided into groups to compare the pain scores of those who received preoperative patient education, the experimental group, and those who did not receive any form of patient education, the control group. Two weeks before surgery, the experimental group subjects received oral and written forms of patient education consisting of how the body responds to pain, and how endorphins cause natural analgesia. Moreover, patients were educated on the negative effects narcotics have on endorphin production and activity, as well as mechanisms of non-opioid analgesics. Of the 69 patients in the experimental group, 90% declined a prescription for hydrocodone after receiving preoperative education two weeks prior to surgery. The control group consisted of 66 patients who did not receive preoperative patient education and 100% filled their hydrocodone prescriptions. Patients in both groups were offered and received gabapentin and celecoxib preoperatively for prophylaxis of postoperative pain unless they declined. The control groups were found to have average pain scores significantly greater (P <.05) than the experimental groups and also a significantly longer (P <.005) duration of pain. This study illustrates the power of patient education via oral, written and visual communication, which can serve as an effective means to minimize narcotic analgesia after surgery.


Subject(s)
Analgesics, Opioid/therapeutic use , Communication , Pain, Postoperative/drug therapy , Patient Education as Topic , Patient Preference , Acetaminophen/therapeutic use , Adult , Amines/therapeutic use , Analgesics/therapeutic use , Celecoxib , Cyclohexanecarboxylic Acids/therapeutic use , Drug Prescriptions , Endorphins/physiology , Gabapentin , Humans , Hydrocodone/therapeutic use , Middle Aged , Pain Management , Pain Measurement , Preoperative Care , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Young Adult , gamma-Aminobutyric Acid/therapeutic use
10.
Hawaii J Med Public Health ; 71(5): 120-3, 2012 May.
Article in English | MEDLINE | ID: mdl-22737648

ABSTRACT

Dry eye syndrome is a potential complication of botulinum toxin type-A injection (BTX-A) into the lateral canthal rhytids (crow's feet). The early manifestations of this syndrome are subtle and are rarely reported to the treating physician. A guideline for early detection of dry-eye state is proposed, in order to avoid more troublesome adverse effects that may develop with repeated injections of BTX-A into the crow's feet region. If suspected early, clinical manifestations remain minor and are reversible. However, delayed diagnosis may lead to troublesome and persistent symptoms. A novel and practical grading scale of lower eyelid snap-back and distraction tests is offered that helps in documenting patient's clinical progress and in deciding when BTX-A injections should be delayed or discontinued.


Subject(s)
Botulinum Toxins, Type A/adverse effects , Dry Eye Syndromes/prevention & control , Neuromuscular Agents/adverse effects , Practice Guidelines as Topic , Botulinum Toxins, Type A/administration & dosage , Dry Eye Syndromes/diagnosis , Dry Eye Syndromes/etiology , Eyelids/drug effects , Humans , Neuromuscular Agents/administration & dosage , Public Health , Severity of Illness Index
18.
Hawaii Med J ; 68(3): 66-8, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19441617

ABSTRACT

PURPOSE: Breast reconstruction with expander/implants is generally discouraged in patients who have undergone radiation therapy. However, not every patient treated with radiation develops sequelae severe enough to preclude the use of prostheses. To date, there have been no studies that have established criteria for selecting which patients may still be considered for expander/implant reconstruction. We present a series of 27 patients--the largest of its kind to date--all of whom underwent bilateral mastectomies, radiation therapy to only one chest wall, and delayed reconstruction with submuscular expander/implants. The aesthetic outcomes of the irradiated and the non-irradiated breasts were compared, and a classification of post-radiation skin changes was devised for selecting candidates for expander/implant reconstruction. METHODS: Patient records were reviewed to identify those who had undergone bilateral mastectomies, radiation treatment to only one chest wall, and delayed expander/implant reconstructions of both breasts. Twenty-seven patients were identified who met our inclusion criteria. Early post-radiation skin changes were classified as "moderate" or "severe," while aesthetic assessments were classified as "good," "acceptable" or "poor." RESULTS: Irradiated chest walls with moderate skin changes and absent induration have aesthetic outcomes comparable to the nonirradiated chest walls (p > 0.50). In contrast, patients who develop induration or severe post-radiation skin changes have a greater rate of modified Baker class IV capsular contracture and poor results that range from 75% to 100% of reconstructed breasts. CONCLUSIONS: A history of chest wall radiation should not itself exclude patients from receiving expander/implant reconstruction. Patients who develop neither severe skin changes nor induration may still be considered for prostheses.


Subject(s)
Breast Implantation/methods , Breast Implants , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Mammaplasty/methods , Radiotherapy/adverse effects , Esthetics , Female , Humans , Mastectomy , Middle Aged , Patient Selection , Thoracic Wall/radiation effects , Treatment Outcome
19.
Aesthetic Plast Surg ; 33(1): 98-103, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18712436

ABSTRACT

BACKGROUND: In 2005 we reported a study on the efficacy of the preoperative use of the selective COX-2 inhibitor celecoxib (Celebrex) for reducing both postoperative pain and opioid requirements in patients undergoing bilateral subpectoral breast augmentation. Our findings showed that patients who received 400 mg of celecoxib 30 min before surgery required significantly less postoperative opioid analgesics compared with those given a placebo. Gabapentin (Neurontin) is an agent commonly used to control neuropathic pain. Here we describe a prospective study assessing the efficacy of preoperative gabapentin in combination with celecoxib for reducing postoperative pain and opioid requirements in elective subpectoral breast augmentation. METHODS: One hundred eighteen patients were given 1200 mg of gabapentin and 400 mg of celecoxib 30-60 min before surgery. From the day of surgery until postoperative day 5, patients documented any use of analgesics and recorded their degree of pain. Results were then compared with those of our previous study in which only celecoxib was used. RESULTS: The combination of gabapentin and celecoxib was found to be significantly superior (p < 0.001) in reducing postoperative pain and opioid requirements than celecoxib alone in the management of postoperative pain and opioid requirements. CONCLUSION: To decrease postoperative opioid requirements, we recommend 400 mg of celecoxib and 1200 mg of gabapentin taken 30-60 min before surgery by patients undergoing subpectoral breast augmentation or a comparable plastic surgery procedure.


Subject(s)
Amines/administration & dosage , Breast Implantation/methods , Cyclohexanecarboxylic Acids/administration & dosage , Pain, Postoperative/prevention & control , Pyrazoles/administration & dosage , Sulfonamides/administration & dosage , gamma-Aminobutyric Acid/administration & dosage , Administration, Oral , Adult , Analgesics, Opioid/administration & dosage , Breast Implantation/adverse effects , Celecoxib , Cohort Studies , Drug Administration Schedule , Drug Therapy, Combination , Female , Follow-Up Studies , Gabapentin , Humans , Middle Aged , Pain Measurement , Pain, Postoperative/physiopathology , Patient Satisfaction , Preoperative Care/methods , Retrospective Studies , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL